129 related articles for article (PubMed ID: 38598020)
1. BRAF and RET polymorphism association with thyroid cancer risk, a preliminary study from Khyber Pakhtunkhwa population.
Batool M; Khan NU; Khan H; Almutairi MH; Ali I; Adams BD
Mol Biol Rep; 2024 Apr; 51(1):502. PubMed ID: 38598020
[TBL] [Abstract][Full Text] [Related]
2. Polymorphisms Within the
Gemignani F; Romei C; Ciampi R; Corrado A; Melaiu O; Figlioli G; Bonotti A; Foddis R; Cristaudo A; Pellegrini G; Vivaldi A; Cipollini M; Landi S; Elisei R
Thyroid; 2020 Nov; 30(11):1579-1588. PubMed ID: 32228166
[No Abstract] [Full Text] [Related]
3. Concomitant BRAF(V600E) mutation and RET/PTC rearrangement is a frequent occurrence in papillary thyroid carcinoma.
Guerra A; Zeppa P; Bifulco M; Vitale M
Thyroid; 2014 Feb; 24(2):254-9. PubMed ID: 23806056
[TBL] [Abstract][Full Text] [Related]
4. [Frequency of RET/PTC rearrangement and somatic BRAF mutation in papillary thyroid cancer].
Rumiantsev PO; Zaletaev DV; Vasil'ev EV; Saenko VA; Il'in AA; Rumiantseva UV; Abrosimov AIu; Medvedev VS
Vopr Onkol; 2006; 52(2):145-9. PubMed ID: 17195637
[TBL] [Abstract][Full Text] [Related]
5. Concomitant RAS, RET/PTC, or BRAF mutations in advanced stage of papillary thyroid carcinoma.
Zou M; Baitei EY; Alzahrani AS; BinHumaid FS; Alkhafaji D; Al-Rijjal RA; Meyer BF; Shi Y
Thyroid; 2014 Aug; 24(8):1256-66. PubMed ID: 24798740
[TBL] [Abstract][Full Text] [Related]
6.
Pekova B; Sykorova V; Dvorakova S; Vaclavikova E; Moravcova J; Katra R; Astl J; Vlcek P; Kodetova D; Vcelak J; Bendlova B
Thyroid; 2020 Dec; 30(12):1771-1780. PubMed ID: 32495721
[No Abstract] [Full Text] [Related]
7. Genotyping of an Italian papillary thyroid carcinoma cohort revealed high prevalence of BRAF mutations, absence of RAS mutations and allowed the detection of a new mutation of BRAF oncoprotein (BRAF(V599lns)).
Carta C; Moretti S; Passeri L; Barbi F; Avenia N; Cavaliere A; Monacelli M; Macchiarulo A; Santeusanio F; Tartaglia M; Puxeddu E
Clin Endocrinol (Oxf); 2006 Jan; 64(1):105-9. PubMed ID: 16402937
[TBL] [Abstract][Full Text] [Related]
8. Inhibitors of Raf kinase activity block growth of thyroid cancer cells with RET/PTC or BRAF mutations in vitro and in vivo.
Ouyang B; Knauf JA; Smith EP; Zhang L; Ramsey T; Yusuff N; Batt D; Fagin JA
Clin Cancer Res; 2006 Mar; 12(6):1785-93. PubMed ID: 16551863
[TBL] [Abstract][Full Text] [Related]
9. Mutational screening of RET, HRAS, KRAS, NRAS, BRAF, AKT1, and CTNNB1 in medullary thyroid carcinoma.
Schulten HJ; Al-Maghrabi J; Al-Ghamdi K; Salama S; Al-Muhayawi S; Chaudhary A; Hamour O; Abuzenadah A; Gari M; Al-Qahtani M
Anticancer Res; 2011 Dec; 31(12):4179-83. PubMed ID: 22199277
[TBL] [Abstract][Full Text] [Related]
10. Clinical, genetic, and immunohistochemical characterization of 70 Ukrainian adult cases with post-Chornobyl papillary thyroid carcinoma.
Dinets A; Hulchiy M; Sofiadis A; Ghaderi M; Höög A; Larsson C; Zedenius J
Eur J Endocrinol; 2012 Jun; 166(6):1049-60. PubMed ID: 22457234
[TBL] [Abstract][Full Text] [Related]
11. Classical point mutations of RET, BRAF and RAS oncogenes are not shared in papillary and medullary thyroid cancer occurring simultaneously in the same gland.
Ciampi R; Romei C; Pieruzzi L; Tacito A; Molinaro E; Agate L; Bottici V; Casella F; Ugolini C; Materazzi G; Basolo F; Elisei R
J Endocrinol Invest; 2017 Jan; 40(1):55-62. PubMed ID: 27535135
[TBL] [Abstract][Full Text] [Related]
12. Possible Impact of RET Polymorphism and Its Haplotypic Association Modulates the Susceptibility to Thyroid Cancer.
Khan MS; Pandith AA; Iqbal M; Naykoo NA; Khan SH; Rather TA; Mudassar S
J Cell Biochem; 2015 Aug; 116(8):1712-8. PubMed ID: 25736215
[TBL] [Abstract][Full Text] [Related]
13. Mutational and clinico-pathological analysis of papillary thyroid carcinoma in Serbia.
Stanojevic B; Dzodic R; Saenko V; Milovanovic Z; Pupic G; Zivkovic O; Markovic I; Djurisic I; Buta M; Dimitrijevic B; Rogounovitch T; Mitsutake N; Mine M; Shibata Y; Nakashima M; Yamashita S
Endocr J; 2011; 58(5):381-93. PubMed ID: 21498916
[TBL] [Abstract][Full Text] [Related]
14. BRAF mediates RET/PTC-induced mitogen-activated protein kinase activation in thyroid cells: functional support for requirement of the RET/PTC-RAS-BRAF pathway in papillary thyroid carcinogenesis.
Mitsutake N; Miyagishi M; Mitsutake S; Akeno N; Mesa C; Knauf JA; Zhang L; Taira K; Fagin JA
Endocrinology; 2006 Feb; 147(2):1014-9. PubMed ID: 16254036
[TBL] [Abstract][Full Text] [Related]
15. Fusion Oncogenes Are the Main Genetic Events Found in Sporadic Papillary Thyroid Carcinomas from Children.
Cordioli MI; Moraes L; Bastos AU; Besson P; Alves MT; Delcelo R; Monte O; Longui C; Cury AN; Cerutti JM
Thyroid; 2017 Feb; 27(2):182-188. PubMed ID: 27849443
[TBL] [Abstract][Full Text] [Related]
16. Relevance of BRAF(V600E) mutation testing versus RAS point mutations and RET/PTC rearrangements evaluation in the diagnosis of thyroid cancer.
Rossi M; Buratto M; Tagliati F; Rossi R; Lupo S; Trasforini G; Lanza G; Franceschetti P; Bruni S; Degli Uberti E; Zatelli MC
Thyroid; 2015 Feb; 25(2):221-8. PubMed ID: 25333496
[TBL] [Abstract][Full Text] [Related]
17. RET/PTC rearrangements preferentially occurred in papillary thyroid cancer among atomic bomb survivors exposed to high radiation dose.
Hamatani K; Eguchi H; Ito R; Mukai M; Takahashi K; Taga M; Imai K; Cologne J; Soda M; Arihiro K; Fujihara M; Abe K; Hayashi T; Nakashima M; Sekine I; Yasui W; Hayashi Y; Nakachi K
Cancer Res; 2008 Sep; 68(17):7176-82. PubMed ID: 18757433
[TBL] [Abstract][Full Text] [Related]
18. Differential responses of human papillary thyroid cancer cell lines carrying the RET/PTC1 rearrangement or a BRAF mutation to MEK1/2 inhibitors.
Henderson YC; Fredrick MJ; Clayman GL
Arch Otolaryngol Head Neck Surg; 2007 Aug; 133(8):810-5. PubMed ID: 17709622
[TBL] [Abstract][Full Text] [Related]
19. Multiple genetic alterations in papillary thyroid cancer are associated with younger age at presentation.
Moses W; Weng J; Khanafshar E; Duh QY; Clark OH; Kebebew E
J Surg Res; 2010 May; 160(2):179-83. PubMed ID: 19765726
[TBL] [Abstract][Full Text] [Related]
20. Detection of papillary thyroid carcinoma by analysis of BRAF and RET/PTC1 mutations in fine-needle aspiration biopsies of thyroid nodules.
Musholt TJ; Fottner C; Weber MM; Eichhorn W; Pohlenz J; Musholt PB; Springer E; Schad A
World J Surg; 2010 Nov; 34(11):2595-603. PubMed ID: 20652698
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
